RARA and intrahepatic cholangiocarcinoma: Consistently, pre‐treatment of BMS195614 (a selective RARα activation antagonist) also rescued the inhibition of SFT on the colony spheroid growth as well as the migration and invasion (Figure 2H,I), indicating that RARα is a potential target of SFT in ICC‐TRCs.